Literature DB >> 10620503

Modulation of tau phosphorylation and intracellular localization by cellular stress.

S M Jenkins1, M Zinnerman, C Garner, G V Johnson.   

Abstract

Tau is a microtubule-associated protein that is functionally modulated by phosphorylation and hyperphosphorylated in several neurodegenerative diseases. Because phosphorylation regulates both normal and pathological tau functioning, it is of great interest to identify the signalling pathways and enzymes capable of modulating tau phosphorylation in vivo. The present study examined changes in tau phosphorylation and localization in response to osmotic stress, which activates the stress-activated protein kinases (SAPKs), a family of proline-directed protein kinases shown to phosphorylate tau in vitro and hypothesized to phosphorylate tau in Alzheimer's disease. Immunoblot analysis with phosphorylation-dependent antibodies revealed that osmotic stress increased tau phosphorylation at the non-Ser/Thr-Pro sites Ser-262/356, within the microtubule-binding domain, as well as Ser/Thr-Pro sites outside of tau's microtubule-binding domain. Although all SAPKs examined were activated by osmotic stress, none of the endogenous SAPKs mediated the increase in tau phosphorylation. However, when transfected into SH-SY5Y cells, SAPK3, but not the other SAPKs examined, phosphorylated tau in situ in response to activation by osmotic stress. Osmotic-stress-induced tau phosphorylation correlated with a decrease in the amount of tau associated with the cytoskeleton and an increase in the amount of soluble tau. This stress-induced alteration in tau localization was only partially due to phosphorylation at Ser-262/356 by a staurosporine-sensitive, non-proline-directed, protein kinase. Taken together, these results suggest that osmotic stress activates at least two tau-directed protein kinases, one proline-directed and one non-proline-directed, that SAPK3 can phosphorylate tau on Ser/Thr-Pro residues in situ, and that Ser-262/356 phosphorylation only partially regulates tau localization in the cell.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620503      PMCID: PMC1220755     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

Authors:  M Hong; D C Chen; P S Klein; V M Lee
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

3.  A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein.

Authors:  T Kawamata; T Taniguchi; H Mukai; M Kitagawa; T Hashimoto; K Maeda; Y Ono; C Tanaka
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

Review 4.  The stress activated protein kinase pathway.

Authors:  J R Woodgett; J Avruch; J Kyriakis
Journal:  Cancer Surv       Date:  1996

Review 5.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.

Authors:  U T Rüegg; G M Burgess
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

6.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

7.  Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location.

Authors:  G I Szendrei; V M Lee; L Otvos
Journal:  J Neurosci Res       Date:  1993-02-01       Impact factor: 4.164

8.  Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules.

Authors:  B Trinczek; J Biernat; K Baumann; E M Mandelkow; E Mandelkow
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

9.  Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.

Authors:  M Goedert; R Jakes; R A Crowther; P Cohen; E Vanmechelen; M Vandermeeren; P Cras
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

10.  Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells.

Authors:  C J Smith; B H Anderton; D R Davis; J M Gallo
Journal:  FEBS Lett       Date:  1995-11-20       Impact factor: 4.124

View more
  8 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

2.  Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.

Authors:  I Ferrer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 3.  Progressive supranuclear palsy.

Authors:  K Tawana; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

Review 4.  Gene-environment interplay in neurogenesis and neurodegeneration.

Authors:  Tomás Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

5.  Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1.

Authors:  Ji-Wu Wang; Yuzuru Imai; Bingwei Lu
Journal:  J Neurosci       Date:  2007-01-17       Impact factor: 6.167

Review 6.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

7.  The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule.

Authors:  Daniel C Carrettiero; Israel Hernandez; Pierre Neveu; Thales Papagiannakopoulos; Kenneth S Kosik
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

8.  Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model.

Authors:  Shreyasi Chatterjee; Tzu-Kang Sang; George M Lawless; George R Jackson
Journal:  Hum Mol Genet       Date:  2008-10-17       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.